Infection
Update

Topics

toumei ../../image Congress Report


13th ECCMID
New Era in the Management of Infectious Diseases May 10-13, 2003


The 13th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) was recently held in Glasgow, Scotland, and certainly lived up to its expectations as the premier European scientific congress in its field. International participants were able to take part in a wide range of scientific presentations, including keynote lectures, symposia, workshops, meet-the-expert sessions, study groups and, as expected, a huge array of thought provoking posters. Throughout this feast of scientific information, it was apparent that the judicious and evidence-based use of antimicrobials was an integral therapeutic consideration, and in particular that fluoroquinolones were continuing to carve out an important and expanding niche for themselves. Among the fluoroquinolones discussed, levofloxacin was one of the most often cited, with an impressive depth of literature supporting its efficacy and safety in many different clinical settings. In addition to the clinical utility of this agent, many sessions emphasized the need for fluoroquinolone therapy in the face of increasing resistance to other classes of antimicrobials. This supplement offers the reader a summary of some of the most interesting and clinically useful presentations relating to levofloxacin, covering both clinical considerations as well as its continuing activity profile against many multi-drug resistant pathogens.

Highlights of Integrated Symposium:
At-risk Patients: the Need for a Large Spectrum Antibiotic


The respiratory fluoroquinolone, levofloxacin, has built up an impressive clinical database demonstrating efficacy and safety in the management of many infectious diseases. It is therefore a sign of its excellent clinical utility that even ten years since its launch, the indications for levofloxacin continue to expand. One such indication is the management of patients with more severe disease, or those at risk for developing serious infection. An important symposium, arranged by Aventis Pharma S. A. was held on May 12. Co-chaired by Professor Emilio Bouza, Madrid, Spain, and Professor Wolfgang Graninger, Vienna, Austria, the symposium highlighted the use of levofloxacin in at-risk patients, from upper respiratory tract infections (URTIs), through to community-acquired pneumonia (CAP) and prostatitis.

Co-Chairman: Prof. Emilio Bouza and Prof. Wolfgang Graninger

  To read the reports click on the title.
   
Professor Emilio Bouza, MD, PhD(left) and Professor Wolfgang Graninger, MD, PhD
Co-chairmen of the Symposium, Professor Emilio Bouza, MD, PhD (left), University of Madrid and Director of the Microbiology and Infections Disease Unit, Hospital General Universatrio Gregorio Marañón, Madrid, Spain and Professor Wolfgang Graninger, MD, PhD, Head of the Division of Infectious Diseases and Chemotherapy, University of Vienna, Vienna, Austria.
   
Professor Dominique Stoll, MD
Risks of complicated sinusitis
Professor Dominique Stoll, MD
Bordeaux University of Medicine and ENT surgeon at Pellegrin University Hospital, Bordeaux, France
   
Doctor Torsten T. Bauer, MD The At-risk Patient with Lower Respiratory Tract Infection
Doctor Torsten T. Bauer, MD
Senior Physician, Berufgenossenschaftliche Kliniken Bergmannsheil, University of Bochum, Bochum, Germany
   
Professor Wolfgang Graninger, MD, PhD The At-risk Patient in the Hospital Setting
Professor Wolfgang Graninger, MD, PhD
Head of the Division of Infectious Diseases and Chemotherapy, University of Vienna, Vienna, Austria
   
Professor Kurt G. Naber, MD Difficulties in the Treatment of Prostatitis
Professor Kurt G. Naber, MD, PhD
Department of Urology at the Technical University of Munich, Head of the Urologic Clinic of the University St. Elisabeth, Straubing, Germany
   


Summarizing the Scientific Sessions
  — Levofloxacin maintains its excellent antibacterial activity profile

Pneumococcal Bacteremia Successfully Treated by Levofloxacin
  Progression from Mild COPD to More Severe Disease Potentially Halted by Levofloxacin
  Excellent PK Parameters Associated with Levofloxacin in ICU Patients
  Increasing Concerns Over Antimicrobial Resistance
  Macrolide Efficacy Limited by Resistance

to_top



 

.
  ©1998- BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.
Disclaimer
Last updated August 8, 2003